A team from the University of Barcelona has designed and validated in animal models an innovative compound with a pioneering mechanism of action for the treatment of Alzheimer’s disease. Unlike current drugs, which mainly remove beta-amyloid plaques that accumulate in the brain, this new experimental drug reprograms the neuronal epigenome by correcting alterations in gene expression that contribute to the progression of the disease.
This article was originally published on MedicalXpress.com

